Opioid Dependency to get Treated with SL-BUP and XR-BUP Introduction into the Patients
Release Date: 16-Nov-2020
A group of researchers from the University of Colorado School of Medicine have stated that three individuals who received low dose of buprenorphine as a single extended release treatment against opioid dependency. Among the three patients who were studied, one with had opioid and alcohol use disorders achieved remission from his opioid use disorder (OUD) for 6 years after using sublingual buprenorphine (SL-BUP). After using sublingual buprenorphine (SL-BUP) daily, the patient received single 100 mg subcutaneous injection of extended-release buprenorphine (XR-BUP). There was an improvement in the patients with respect to constipation symptoms and episodes of depersonalization.
Another patient enrolled in the study received 6 mg daily dose of SL-BUP for 14 months and finally she was able to taper down to minimum 2mg dose of the SL-BUP. After receiving SL-BUP, she received XR-BUP injection and following this no withdrawal symptoms no symptoms were reported. Another female enrolled in the study was able to transition to 12 mg SL-BUP for 12 months and after several months she was able to go down to 6mg of SL-BUP. She also received similar injection of XR-BUP post SL-BUP. It was concluded from the study that doses of SL-BUP was able to treat the patients who had opioid dependency for prolonged period of time.
Need custom market research solution? We can help you with that too.
Kuick Research is a market research and analytics company that provides targeted information for critical decisions at business, product and
service levels. We are quick, predictive and known by the recommendations we have made in the past. Our result-oriented research methodology offers
understanding of multiple issues in a short period of time and gives us the capability to keep you full with loads of practical ideas.